论文信息 - FRI0161 Sustained Efficacy and Comparable Safety and Immunogenicity after Transition To SB5 (An Adalimumab Biosimilar) vs Continuation of The Adalimumab Reference Product in Patients with Rheumatoid Arthritis: Result of Phase III Study - 字舞流文

FRI0161 Sustained Efficacy and Comparable Safety and Immunogenicity after Transition To SB5 (An Adalimumab Biosimilar) vs Continuation of The Adalimumab Reference Product in Patients with Rheumatoid Arthritis: Result of Phase III Study

V. Zhdan | M. Weinblatt | J. Jaworski | E. Dokoupilová | A. Zielinska | S. Cheong | M. Pileckyte | K. Sitek-Ziółkowska | J. Niebrzydowski | K. Jedrychowicz-Rosiak | A. Baranauskaite | A. Racewicz | J. Ghil